144 related articles for article (PubMed ID: 5661914)
41. [Vancomycin at the very lowest infusion rate and red man's syndrome].
Rengo C; Vetrano A; D'Amato T; Rengo F
Recenti Prog Med; 1992 Dec; 83(12):726. PubMed ID: 1494713
[No Abstract] [Full Text] [Related]
42. [Cutaneous staphylococcus aureus infection treated with fucidin ointment].
Sobye P
Ugeskr Laeger; 1966 Feb; 128(7):204-6 passim. PubMed ID: 5961741
[No Abstract] [Full Text] [Related]
43. Influence of in vitro susceptibility phenotype against thrombin-induced platelet microbicidal protein on treatment and prophylaxis outcomes of experimental Staphylococcus aureus endocarditis.
Dhawan VK; Yeaman MR; Bayer AS
J Infect Dis; 1999 Nov; 180(5):1561-8. PubMed ID: 10515816
[TBL] [Abstract][Full Text] [Related]
44. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis.
Gentry CA; Rodvold KA; Novak RM; Hershow RC; Naderer OJ
Pharmacotherapy; 1997; 17(5):990-7. PubMed ID: 9324187
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of vancomycin, teicoplanin and fusidic acid as prophylactic agents in prevention of vascular graft infection: an experimental study in rat.
Yasim A; Gul M; Atahan E; Ciragil P; Aral M; Ergun Y
Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):274-9. PubMed ID: 16360328
[TBL] [Abstract][Full Text] [Related]
46. [Management of staphylococcal infections using Fucidin].
Spelsberg F; Sixt H; Meyer A
Munch Med Wochenschr; 1966 May; 108(18):997-9. PubMed ID: 6014846
[No Abstract] [Full Text] [Related]
47. [Vancomycin and teicoplanin: differential aspects].
Cobo J
Enferm Infecc Microbiol Clin; 1995 Dec; 13(10):600-10. PubMed ID: 8808477
[No Abstract] [Full Text] [Related]
48. Methicillin resistance in Staphylococcus aureus with particular reference to Victorian strains.
Harvey K; Pavillard R
Med J Aust; 1982 May; 1(11):465-7. PubMed ID: 7048040
[TBL] [Abstract][Full Text] [Related]
49. Fusidic acid as a potential antistaphylococcal agent.
Nicholson J; Chew T; Smith S
N Z Med J; 1999 Jul; 112(1091):261-2. PubMed ID: 10448991
[No Abstract] [Full Text] [Related]
50. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
51. Lack of evidence associating nephrotoxicity with low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis.
Bruss JB
Clin Infect Dis; 2009 Sep; 49(5):806; author reply 807-8. PubMed ID: 19653850
[No Abstract] [Full Text] [Related]
52. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
53. Clinical usefulness of vancomycin.
Cunha BA; Ristuccia AM
Clin Pharm; 1983; 2(5):417-24. PubMed ID: 6354567
[TBL] [Abstract][Full Text] [Related]
54. [Treatment of mitral MRSA endocarditis using daptomycin].
Senneville E; Beltrand E; Legout L; Leroy O; Fayad G
Med Mal Infect; 2008 Dec; 38 Spec No 2():13-5. PubMed ID: 19185204
[No Abstract] [Full Text] [Related]
55. Treatment of Staphylococcus aureus prosthetic valve endocarditis.
Hassoun A
Am J Med; 2007 Mar; 120(3):e9; author reply e11. PubMed ID: 17349434
[No Abstract] [Full Text] [Related]
56. [Severe resistant staphylococcal infections. Treatment with a rifampicine-vancomycin combination].
Preux MC; Dusehu E; Veyssier P
Nouv Presse Med; 1980 Oct; 9(39):2918-9. PubMed ID: 7443425
[No Abstract] [Full Text] [Related]
57. Staph with lower vancomycin resistance in US.
OR Manager; 1997 Oct; 13(10):7. PubMed ID: 10174189
[No Abstract] [Full Text] [Related]
58. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
[TBL] [Abstract][Full Text] [Related]
59. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.
Lodise TP; McKinnon PS; Levine DP; Rybak MJ
Antimicrob Agents Chemother; 2007 Oct; 51(10):3731-3. PubMed ID: 17664322
[TBL] [Abstract][Full Text] [Related]
60. [Right endocarditis caused by Staphylococcus aureus in parenteral drug addicts: evaluation of a combined therapeutic scheme for 2 weeks versus conventional treatment].
Espinosa FJ; Valdés M; Martín-Luengo F; Arribas JP; Albaladejo J; Pérez-Gracia A; García-Henarejos JA; Martínez-Madrid O; García-Alberola A
Enferm Infecc Microbiol Clin; 1993 May; 11(5):235-40. PubMed ID: 8324018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
